Theolytics
5 known investors
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment. It uses its Adenovo platform to screen large libraries of adenovirus variants in human systems to identify therapeutic candidates, with THEO-260 as its lead programme.
Investors · 5
Frequently asked questions
- What does Theolytics do?
- Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment. It uses its Adenovo platform to screen large libraries of adenovirus variants in human systems to identify therapeutic candidates, with THEO-260 as its lead programme.
- Who are Theolytics's investors?
- Theolytics's investors include Epidarex Capital, Oxford Science Enterprises, Sound Bioventures, Taiho Ventures, LLC, M Ventures.